NEW YORK (GenomeWeb) – Raymond James today upgraded its rating for shares of Quest Diagnostics to Outperform, based on expected growth in professional laboratory services and M&A activity.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.